Trial Profile
A retrospective real-world study of PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Programmed cell death-1 ligand-1 inhibitors
- Indications Prostate cancer
- Focus Therapeutic Use
- 22 Mar 2023 New trial record
- 01 Mar 2023 Results published in the Asian Journal of Andrology